StreetInsider.com News Articles

Onco-Innovations amends private placement pricing to $0.65 per unit

Thu, 12 Feb 2026 09:01:17 -0500

Onco-Innovations Limited (CBOE CA: ONCO) announced it has amended the pricing of its previously announced non-brokered private placement. The company now intends to issue up to 3,076,923 units at $0.65 per unit, targeting aggregate gross proceeds of up to $2 million.

Each unit consists of one common share and one share purchase warrant. The warrants are exercisable at $0.75 per share for three years. The company also plans to issue shares equal to 1% of the total shares issued as administrative fees to a third party.

Onco-Innovations may pay finders' fees or issue finders' warrants to parties who introduce subscribers to the

Onco-Innovations Announces Amendment to Private Placement Pricing

Thu, 12 Feb 2026 09:00:00 -0500

Not for distribution to United States wire services or for dissemination in the United States

VANCOUVER, BC / ACCESS Newswire / February 12, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") announces that it has amended the pricing of its previously-announced (see news release dated January 23, 2026) non-brokered private placement (the "Amended Private Placement"). Under the Amended Private Placement, the Company intends to issue up to 3,076,9233 units (each, a "Unit'') at a price of $0.65 per Unit, for aggregate gross proceeds of up to $2,000,000. Each Unit

Onco-Innovations Announces Amendment to Private Placement Pricing

Thu, 12 Feb 2026 09:00:00 -0500

Not for distribution to United States wire services or for dissemination in the United States

Onco-Innovations Announces Filing of Preliminary Base Shelf Prospectus

Wed, 04 Feb 2026 18:00:00 -0500

VANCOUVER, BC / ACCESS Newswire / February 4, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") announces that it has filed a preliminary base shelf prospectus dated February 3, 2026 (the "Base Shelf Prospectus") with the securities regulatory authorities in each of the provinces of Alberta, British Columbia, Manitoba and Ontario. The Base Shelf Prospectus has been filed, but is not yet final, and the securities described therein may not be sold until (i) a receipt for a final short form base shelf prospectus is obtained from the applicable

Onco-Innovations Announces Filing of Preliminary Base Shelf Prospectus

Wed, 04 Feb 2026 18:00:00 -0500

Onco-Innovations plans $2 million private placement at $0.88 per unit

Fri, 23 Jan 2026 19:00:10 -0500

Onco-Innovations Limited (CBOE CA: ONCO) announced plans for a non-brokered private placement to raise up to $2 million through the sale of 2,272,727 units at $0.88 each.

Each unit consists of one common share and half of a common share purchase warrant. The warrants allow holders to purchase additional shares at $1.10 each within 36 months of issuance.

The Vancouver-based cancer research company will issue additional shares equal to 1% of the total placement as administrative fees to a third party assisting with the transaction. The company may also pay finders' fees or issue finders' warrants to parties who introduce subscribers.

Completion of

Onco-Innovations Announces Private Placement

Fri, 23 Jan 2026 19:00:00 -0500

Not for distribution to United States wire services or for dissemination in the United States

VANCOUVER, BC / ACCESS Newswire / January 23, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN:A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") announces that it intends to complete a non-brokered private placement (the "Private Placement") of up to 2,272,727 units of the Company (the "Units") at a price of $0.88 per Unit, for aggregate gross proceeds of up to $2,000,000. Each Unit shall consist of one common share (each a "Share") and one-half of one common share purchase warrant (each whole

Onco-Innovations Announces Private Placement

Fri, 23 Jan 2026 19:00:00 -0500

Not for distribution to United States wire services or for dissemination in the United States

Onco-Innovations Engages i2i Marketing Group Engagement for Market Awareness Services

Wed, 21 Jan 2026 18:00:00 -0500

VANCOUVER, BC / ACCESS Newswire / January 21, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") announces that it has engaged i2i Marketing Group, LLC (1107 Key Plaza, Suite 222, Key West, FL 33040, USA; email: contact@i2illc.com; telephone: (240) 315-4665; Contact: Joe Grubb) to provide market awareness and corporate communications services, including through content creation, project management, third-party media distribution, and digital market awareness initiatives.

The Company also announces that it has obtained a return of the remaining unused balance of €213,000 from its prior market awareness

Onco-Innovations Engages i2i Marketing Group Engagement for Market Awareness Services

Wed, 21 Jan 2026 18:00:00 -0500

The Company also announces that it has obtained a return of the remaining unused balance of €213,000 from its prior market awareness

Onco-Innovations Chairs Colorectal Cancer Canada Precision Oncology Forum Generating Roadmaps for the Next Era of Cancer Care

Tue, 09 Dec 2025 18:00:00 -0500

VANCOUVER, BC / ACCESS Newswire / December 9, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") is pleased to announce, further to its news release dated September 12, 2025, the completion of the fourth session in Colorectal Cancer Canada's Catalysts: Innovating for Tomorrow Series, led by its subsidiary, Inka Health Corp. ("Inka Health" or "Inka"). The invitation-only virtual roundtable, titled Beyond Borders: Data-Driven Innovation for Global Precision Oncology, held on December 2, 2025, brought together approximately 20 senior leaders from across the oncology ecosystem, including representatives

Onco-Innovations Chairs Colorectal Cancer Canada Precision Oncology Forum Generating Roadmaps for the Next Era of Cancer Care

Tue, 09 Dec 2025 18:00:00 -0500

Onco-Innovations Engages Investment Bank to Pursue Nasdaq Cross-listing and Potential Concurrent Equity Offering

Sun, 07 Dec 2025 03:00:00 -0500

VANCOUVER, BC / ACCESS Newswire / December 7, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has engaged a U.S. investment bank to serve as its capital markets advisor in connection with the Company's intention to pursue a potential cross-listing of its common shares on the Nasdaq Stock Market LLC ("Nasdaq" or the "Exchange") and to evaluate and structure a potential concurrent equity financing. The structure and terms of the contemplated financing have not yet been finalized.

This engagement forms part of the

Onco-Innovations Engages Investment Bank to Pursue Nasdaq Cross-listing and Potential Concurrent Equity Offering

Sun, 07 Dec 2025 03:00:00 -0500

This engagement forms part of the

Onco-Innovations Attends University of Alberta's 2025 Innovation Awards

Tue, 25 Nov 2025 16:30:00 -0500

VANCOUVER, BC / ACCESS Newswire / November 25, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN:A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") is pleased to announce that it was invited to attend the University of Alberta's 2025 Innovation Awards in Edmonton, Alberta, which were held on November 21, 2025. The annual ceremony is meant to recognize outstanding research and innovation that can translate university discoveries into societal and commercial impact.

This year marked the first time the University of Alberta has included technology licensees, highlighting the institution's growing focus on industry collaboration and the advancement of

Onco-Innovations Attends University of Alberta's 2025 Innovation Awards

Tue, 25 Nov 2025 16:30:00 -0500

This year marked the first time the University of Alberta has included technology licensees, highlighting the institution's growing focus on industry collaboration and the advancement of

Onco-Innovations begins scale-up work for cancer drug with Dalton Pharma

Thu, 20 Nov 2025 19:30:11 -0500

Onco-Innovations Limited (CBOE CA: ONCO) announced that manufacturing partner Dalton Pharma Services has started process optimization and intermediate scale-up activities for A83B4C63, the company's PNKP inhibitor technology.

The work focuses on refining and scaling the synthesis process under non-GMP conditions as part of Onco's manufacturing development program to support future clinical material production. Dalton will conduct intermediary scale-up batches targeting approximately 500 grams of precursor A83 and 1,000 grams of precursor B4 to evaluate reaction performance under scale-up conditions.

The activities build on previous manufacturing work Dalton initiated for preclinical testing material in May 2025. The current phase emphasizes process scale-up and

Onco-Innovations Advances Optimization and Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services to Support Future Phase 1 Clinical Studies

Thu, 20 Nov 2025 19:30:00 -0500

VANCOUVER, BC / ACCESS Newswire / November 20, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that its manufacturing partner, Dalton Pharma Services ("Dalton"), has initiated process optimization and intermediate scale-up activities for A83B4C63, the Company's proprietary PNKP Inhibitor Technology. This phase of work is designed to refine and scale the synthesis process under non-GMP conditions as part of Onco's ongoing manufacturing development program, supporting future clinical material production.

Building on the manufacturing activities previously initiated by Dalton for preclinical testing material (see Company press release

Onco-Innovations Advances Optimization and Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services to Support Future Phase 1 Clinical Studies

Thu, 20 Nov 2025 19:30:00 -0500

Building on the manufacturing activities previously initiated by Dalton for preclinical testing material (see Company press release

Onco-Innovations Advances AI and Quantum Drug Discovery with Kuano Collaboration to Accelerate PNKP Inhibitor Technology Development

Tue, 18 Nov 2025 18:00:00 -0500

VANCOUVER, BC / ACCESS Newswire / November 18, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that it is initiating a pilot project with Kuano Ltd. (Kuano) to accelerate development of Onco's PNKP Inhibitor Technology (also known as A83B4C63). This collaboration marks an important step in Onco's mission to harness advanced technologies, in this case computational platforms, to unlock novel cancer treatment mechanisms and drive faster, more precise therapeutic innovation.

This new initiative builds upon Onco's ongoing efforts to enhance the discovery and evaluation of

Onco-Innovations Advances AI and Quantum Drug Discovery with Kuano Collaboration to Accelerate PNKP Inhibitor Technology Development

Tue, 18 Nov 2025 18:00:00 -0500

This new initiative builds upon Onco's ongoing efforts to enhance the discovery and evaluation of

Onco-Innovations' Inka Health Publishes Framework on Transportability of Real-World Evidence and Use in Health Technology Assessment

Fri, 07 Nov 2025 18:00:00 -0500

VANCOUVER, BC / ACCESS Newswire / November 7, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") is pleased to announce that its subsidiary, Inka Health Corp. ("InkaHealth"), has published a technical primer[1] on the transportability of real-world evidence (RWE) titled Transportability of Non-Local Real-World Evidence and Its Relevance to Health Technology Assessment in the Journal of Clinical Evaluative Research (JCER). This primer, co-authored with experts at AstraZeneca Canada, addresses a critical challenge in global healthcare decision-making by demonstrating how advanced statistical transportability methods can adapt medical evidence from

Onco-Innovations' Inka Health Publishes Framework on Transportability of Real-World Evidence and Use in Health Technology Assessment

Fri, 07 Nov 2025 18:00:00 -0500

Onco-Innovations Provides Shareholder Update Following Cboe Canada Investor Spotlight

Fri, 31 Oct 2025 18:00:00 -0500

Focus on U.S. Strategy

VANCOUVER, BC / ACCESS Newswire / October 31, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to provide a corporate update outlining its strategic objectives for the upcoming year. The update follows Onco-Innovations' CEO Thomas O'Shaughnessy's recent appearance on Cboe Canada's Investor Spotlight (October 22, 2025), where he discussed Onco's mission to enhance cancer treatment technologies through innovation, AI-driven research, and strategic growth initiatives.

Over the past several months, Onco has achieved a series of milestones that have strengthened its scientific and operational foundation,

Onco-Innovations Provides Shareholder Update Following Cboe Canada Investor Spotlight

Fri, 31 Oct 2025 18:00:00 -0500

Focus on U.S. Strategy

Over the past several months, Onco has achieved a series of milestones that have strengthened its scientific and operational foundation,